A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a “3+3” design. Successive cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified. Once the maximum tolerated dose is identified, an Expansion Cohort will be enrolled at that dose to further characterize safety and to explore pharmacodynamic endpoints.
For more information, please visit ClinicalTrials.gov
|Patient Population||Investigational Product(s)||Phase||Status|
|Gynecologic and Breast Cancer||MM-121||I||Closed to Accrual|